EOCH PERUANA SRL:

DESCRIPTION

Bopriva® is prepared with a GnRF analog bound to a carrier protein. A synthetic aqueous adjuvant is added to increase the level and duration of immunity.

For the temporary suppression of testosterone in bulls in post-puberty stage, causing the reduction of testosterone-motivated behaviors in non-castrated male cattle, as well as for the regulation of estrus in heifers in post-puberty. It contributes in the improvement of the alimentary conversion and the characteristics of the meat.

INDICATIONS

Bulls: Only healthy animals should be immunized. Bopriva® is indicated for the induction of antibodies against GnRF to produce a temporary immunological suppression of testicular function in post-pubescent bulls. It is an alternative to physical castration for the reduction of blood testosterone levels. The onset of immunity (induction of anti-GnRF antibodies) can be expected within 1 to 2 weeks after the second administration, resulting in the reduction of blood testosterone levels for at least 8 weeks and in Most cases up to 12 weeks after the second administration.

Heifers: Bopriva® is indicated for the induction of antibodies against GnRF, through its inhibitory effect on GnRF and indirectly on luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Bopriva® produces a temporary immunological suppression of ovarian function in heifers in the post-puberty stage, resulting in the temporary suppression of estrogen and progesterone levels in heifers treated with Bopriva®. The normal activity of cyclic estrus begins to decrease or ceases in approximately 2 weeks (14 days) after the second administration with Bopriva®. The onset of immunity in heifers (induction of anti-GnRF antibodies) can be expected 1 to 2 weeks after the second administration. In most heifers maintained under feedlot conditions, it is expected that the suppression of inactive estrus behavior, induced by the product, will last at least 16 weeks after the second administration. If it is desired to achieve a continuous anestrus, it is likely that additional doses of reinforcement will be required.

DOSAGE / ADMINISTRATION

1 ml as part of a 2-dose program.

Recommended administration plan: The primary dose of Bopriva® should be administered 3 weeks before the second dose, that is, 4 to 5 weeks before the start of the desired effect. The second dose of Bopriva®, administered at least 3 weeks after the primary dose.

The duration of suppression of testosterone in bulls can be prolonged by extending the dose range from 3 weeks to 8-12 weeks between the initial and booster doses. It is expected to result in a suppression of testosterone of approximately 16 weeks in most bulls inoculated with Bopriva®.

PRECAUTIONS / WARNINGS

• It is not for use in humans. For exclusive treatment in animals.
  
• Care must be taken to avoid accidental self-injection and needlestick injury when administering this product.
• Your accidental self injection can cause infertility in both men and women, adversely affect pregnancy or cause atrophy of sexual organs.
• In the event that self injection occurs, seek medical attention immediately and do not administer this product in the future.
• It should not be administered by women who might be pregnant. It is not to be used by women of reproductive age.
• Your purchase requires a medical prescription.

Withdrawal period:

Zero days

The use of this product is contraindicated in breeding cattle. Inadvertent administration of any breeding stock of either sex could affect their subsequent fertility.

Transient swelling at the site of the injection may develop after the application resolves within 3 to 5 weeks. The cattle to which Bopriva® is administered may show transient pyrexia and recover its normal temperature within 2 or 3 days after application. Rarely, an anaphylactic reaction to the post-application product may occur that necessitates immediate veterinary treatment.

As with all older cattle groups, care should be taken when handling animals treated with Bopriva® as individual animals inherently nervous or aggressive may still respond unpredictably.

Additional safety information: To help the operator avoid accidental self-injection, this product should be administered using a safety vacciner that has a dual safety system that provides a needle guard and a mechanism to prevent accidental operation of the trigger .

STORAGE

Keep in position